Compare
Bluejay Diagnostics, Inc. vs Medinotec Inc. vs Autonomix Medical, Inc. vs Glucotrack, Inc.
| Latest fiscal year | Bluejay Diagnostics, Inc. BJDX | Medinotec Inc. MDNC | Autonomix Medical, Inc. AMIX | Glucotrack, Inc. GCTKRevenue covers only part of its income (partial revenue) |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-02-28 | 2026-03-31 | 2025-12-31 |
| Revenue | n/a | $9.73M | $0 | n/a |
| Revenue growth (YoY) | n/a | +6.8% | n/a | n/a |
| Gross margin | n/a | 52.7% | n/a | n/a |
| Operating margin | n/a | 11.2% | n/a | n/a |
| Net margin | n/a | 8.2% | n/a | n/a |
| Net income | -$6.85M | $794.5K | -$16.71M | -$19.39M |
| EPS (Diluted) | -$15.25 | n/a | n/a | $31.22 |
| Operating cash flow | -$6.05M | $906.8K | -$12.28M | -$15.24M |
| Free cash flow | -$6.23M | $905.4K | -$12.29M | -$15.34M |
| Cash & equivalents | $5.16M | n/a | $7.00M | $7.38M |
| Total assets | $7.12M | $6.81M | $7.60M | $7.84M |
| Total liabilities | $1.14M | $1.10M | $1.71M | $5.01M |
| Shareholders' equity | $5.98M | $5.71M | $5.89M | $2.83M |
| Return on year-end equity | -114.6% | 13.9% | -283.5% | -685.6% |
| Shares outstanding | 604.5K | 11.76M | 11.41M | 910.7K |
Revenue, most recent five fiscal years
| Fiscal year | Bluejay Diagnostics, Inc. | Medinotec Inc. | Autonomix Medical, Inc. | Glucotrack, Inc. |
|---|---|---|---|---|
| Latest | $249.0K Ended 2022-12-31 | $9.73M Ended 2026-02-28 | $0 Ended 2026-03-31 | n/a |
| 1 year earlier | n/a | $9.11M Ended 2025-02-28 | $0 Ended 2025-03-31 | n/a |
| 2 years earlier | n/a | $5.02M Ended 2024-02-29 | $0 Ended 2024-03-31 | n/a |
| 3 years earlier | n/a | $999.6K Ended 2023-02-28 | $0 Ended 2023-03-31 | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |